InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Kelly Leanne M., Chief Financial Officer. Director active across 1 company, notably Vallon Pharmaceuticals, Inc.. In total, 2 filings have been published. Breakdown: 2 buys · 0 sell. Total volume traded: €24k. History available since 2 June 2021. The latest transaction was disclosed on 2 June 2021 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations2 total
3,657 shares@ US$4.0050.0% of flowCommon StockSEC:0001104659-21-076998:0
Ideal exit: 27 Feb 2022 (T+270)
3,657 shares@ US$4.0050.0% of flowCommon StockSEC:0001104659-21-076998
Ideal exit: 27 Feb 2022 (T+270)
2 of 2 declarations
About Kelly Leanne M.
Leanne M. Kelly is the Chief Financial Officer of Vallon Pharmaceuticals, Inc. She is responsible for the financial management of the company, including budgeting and financial performance analysis. Her role is essential in ensuring Vallon's financial health and supporting its strategic initiatives. Leanne also contributes to the development of the company's overall financial strategy.
